Translational science: past, present, and future.
The concept of translational science is at least 15 years old. However, in its most recent incarnation, it represents the identification of a funding category designed to encourage academic participation in a critical stage of the drug discovery and product development process. It is hoped that this will make the process both shorter and more efficient. In this review, the author first considers the historical development of the pharmaceutical R&D process. The place of translational science in the process, the scientific techniques involved, and aspects of the business environment necessary for its success are then considered. Translational science does not displace preclinical development. Both concepts are relevant to the paramount importance of successfully and expeditiously bridging the gap between preclinical science and clinical testing, "from bench to bedside." Translational science is particularly likely to stimulate biomarker research in the universities and related business community and will probably give a modest boost to early clinical testing and commercialization of discoveries within the academic setting. Whether there will be a consequent improvement in the quality and efficiency of the overall process remains to be seen.
Curry
Stephen H
SH
University of Rochester, Rochester, NY, USA. stephenhcurry@earthlink.net
D015415:Biomarkers; D035843:Biomedical Research / Q000639:trends*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D018581:Technology Transfer
D015415:Biomarkers